explore -WSS

explore

author：entertainment 2025-10-01 23:58:02 - browse：16976

Home health and hospice chain Amedisys has chosen a new corporate owner.

Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Telehealth startups turn to complex chronic diseases

leisure time

WSS

Readout LOUD podcast: What to know about H5N1 bird flu

PBMs drew scrutiny in House hearing — and so did pharma

Medicare says breakthrough device reimbursement rule to come by summer

Google says AlphaFold 3 can map a vast universe of biomolecules

Midwives could help bridge maternal health disparities in the U.S.

Brain worms: The science behind RFK Jr.'s parasitic infection

Wikipedia

explore

Wikipedia

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Brain worms: The science behind RFK Jr.'s parasitic infection

Novavax promises a turnaround & Lilly roils the obesity market

Elevance, private equity launch primary care company

At least 13 dead in Texas as scorching temps continue

Patients, doctors press FTC to beef up hospital merger scrutiny

Cancer drug shortages should be causing more outrage

Fed up with FDA, ALS advocates consider a take

Supreme Court strikes down use of affirmative action

Google says AlphaFold 3 can map a vast universe of biomolecules

knowledge

Neurocrine congenital adrenal hyperplasia trial succeeds

PBMs drew scrutiny in House hearing — and so did pharma

PBMs drew scrutiny in House hearing — and so did pharma

H5N1 bird flu: what we're starting to learn about infection in cows

FDA weighs limits of animal data in assessing artificial wombs

Shionogi licenses Pompe disease therapy from Maze Therapeutics

hotspot

focus

leisure time

focus